These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

724 related articles for article (PubMed ID: 21499684)

  • 1. Cancer risk in Jewish BRCA1 and BRCA2 mutation carriers: effects of oral contraceptive use and parental origin of mutation.
    Bernholtz S; Laitman Y; Kaufman B; Paluch Shimon S; Friedman E
    Breast Cancer Res Treat; 2011 Sep; 129(2):557-63. PubMed ID: 21499684
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phenocopy breast cancer rates in Israeli BRCA1 BRCA2 mutation carrier families: is the risk increased in non-carriers?
    Bernholtz S; Laitman Y; Kaufman B; Shimon-Paluch S; Friedman E
    Breast Cancer Res Treat; 2012 Apr; 132(2):669-73. PubMed ID: 22113258
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
    Satagopan JM; Boyd J; Kauff ND; Robson M; Scheuer L; Narod S; Offit K
    Clin Cancer Res; 2002 Dec; 8(12):3776-81. PubMed ID: 12473589
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age.
    van der Kolk DM; de Bock GH; Leegte BK; Schaapveld M; Mourits MJ; de Vries J; van der Hout AH; Oosterwijk JC
    Breast Cancer Res Treat; 2010 Dec; 124(3):643-51. PubMed ID: 20204502
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Appendectomy and cancer risk in Jewish BRCA1 and BRCA2 mutation carriers.
    Bernholtz S; Jakobson-Setton A; Korach J; Ben Baruch G; Laitman Y; Friedman E
    Breast Cancer Res Treat; 2012 Feb; 131(3):981-5. PubMed ID: 21984204
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functional variant of KLOTHO: a breast cancer risk modifier among BRCA1 mutation carriers of Ashkenazi origin.
    Wolf I; Laitman Y; Rubinek T; Abramovitz L; Novikov I; Beeri R; Kuro-O M; Koeffler HP; Catane R; Freedman LS; Levy-Lahad E; Karlan BY; Friedman E; Kaufman B
    Oncogene; 2010 Jan; 29(1):26-33. PubMed ID: 19802015
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation.
    Modan B; Hartge P; Hirsh-Yechezkel G; Chetrit A; Lubin F; Beller U; Ben-Baruch G; Fishman A; Menczer J; Struewing JP; Tucker MA; Wacholder S;
    N Engl J Med; 2001 Jul; 345(4):235-40. PubMed ID: 11474660
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hormone replacement therapy is more prevalent among Jewish BRCA1/2 mutation carriers.
    Sade RB; Chetrit A; Figer A; Papa MZ; Flex D; Rizel S; Friedman E
    Eur J Cancer; 2006 Mar; 42(5):650-5. PubMed ID: 16464572
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The lifetime risks of breast cancer in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
    Satagopan JM; Offit K; Foulkes W; Robson ME; Wacholder S; Eng CM; Karp SE; Begg CB
    Cancer Epidemiol Biomarkers Prev; 2001 May; 10(5):467-73. PubMed ID: 11352856
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Two patients with germline mutations in both BRCA1 and BRCA2 discovered unintentionally: a case series and discussion of BRCA testing modalities.
    Augustyn AM; Agostino NM; Namey TL; Nair S; Martino MA
    Breast Cancer Res Treat; 2011 Sep; 129(2):629-34. PubMed ID: 21607582
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of a paternal origin of germline BRCA1/2 mutations on the age at breast and ovarian cancer diagnosis in a Southern Swedish cohort.
    Ellberg C; Jernström H; Broberg P; Borg Å; Olsson H
    Genes Chromosomes Cancer; 2015 Jan; 54(1):39-50. PubMed ID: 25251729
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Absence of genomic BRCA1 and BRCA2 rearrangements in Ashkenazi breast and ovarian cancer families.
    Stadler ZK; Saloustros E; Hansen NA; Schluger AE; Kauff ND; Offit K; Robson ME
    Breast Cancer Res Treat; 2010 Sep; 123(2):581-5. PubMed ID: 20221693
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1.
    Lose F; Duffy DL; Kay GF; Kedda MA; Spurdle AB; ;
    J Natl Cancer Inst; 2008 Nov; 100(21):1519-29. PubMed ID: 18957670
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral contraceptives and risk of ovarian and breast cancers in BRCA mutation carriers: a meta-analysis.
    Cibula D; Zikan M; Dusek L; Majek O
    Expert Rev Anticancer Ther; 2011 Aug; 11(8):1197-207. PubMed ID: 21916573
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Oophorectomy on Survival After Breast Cancer in BRCA1 and BRCA2 Mutation Carriers.
    Metcalfe K; Lynch HT; Foulkes WD; Tung N; Kim-Sing C; Olopade OI; Eisen A; Rosen B; Snyder C; Gershman S; Sun P; Narod SA
    JAMA Oncol; 2015 Jun; 1(3):306-13. PubMed ID: 26181175
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Parity and the risk of breast and ovarian cancer in BRCA1 and BRCA2 mutation carriers.
    Milne RL; Osorio A; Ramón y Cajal T; Baiget M; Lasa A; Diaz-Rubio E; de la Hoya M; Caldés T; Teulé A; Lázaro C; Blanco I; Balmaña J; Sánchez-Ollé G; Vega A; Blanco A; Chirivella I; Esteban Cardeñosa E; Durán M; Velasco E; Martínez de Dueñas E; Tejada MI; Miramar MD; Calvo MT; Guillén-Ponce C; Salazar R; San Román C; Urioste M; Benítez J
    Breast Cancer Res Treat; 2010 Jan; 119(1):221-32. PubMed ID: 19370414
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does oral contraceptive use increase the risk of breast cancer in women with BRCA1/BRCA2 mutations more than in other women?
    Ursin G; Henderson BE; Haile RW; Pike MC; Zhou N; Diep A; Bernstein L
    Cancer Res; 1997 Sep; 57(17):3678-81. PubMed ID: 9288771
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single-nucleotide polymorphisms in the p53 pathway genes modify cancer risk in BRCA1 and BRCA2 carriers of Jewish-Ashkenazi descent.
    Yarden RI; Friedman E; Metsuyanim S; Olender T; Ben-Asher E; Papa MZ
    Mol Carcinog; 2010 Jun; 49(6):545-55. PubMed ID: 20306497
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations.
    Rennert G; Bisland-Naggan S; Barnett-Griness O; Bar-Joseph N; Zhang S; Rennert HS; Narod SA
    N Engl J Med; 2007 Jul; 357(2):115-23. PubMed ID: 17625123
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study.
    Eisen A; Lubinski J; Klijn J; Moller P; Lynch HT; Offit K; Weber B; Rebbeck T; Neuhausen SL; Ghadirian P; Foulkes WD; Gershoni-Baruch R; Friedman E; Rennert G; Wagner T; Isaacs C; Kim-Sing C; Ainsworth P; Sun P; Narod SA
    J Clin Oncol; 2005 Oct; 23(30):7491-6. PubMed ID: 16234515
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.